Alterations of Serum Bile Acid Profile in Patients with Crohn’s Disease

Sun, Rui; Jiang, Jingjing; Yang, Ling; Chen, Lu; Chen, Hong

doi:10.1155/2022/1680008

Cited by 3 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, these studies often lacked healthy controls, were limited by small sample sizes, and focused exclusively on BA analysis. [32,33] Our current study, involving a larger cohort of 346 patients, including healthy controls, provides a comprehensive analysis of various metabolites, in addition to BA. We demonstrated signi cant decreases in the ratios of primary to secondary BA in the sera of patients with both CD and UC when compared with NC (Fig.…”

Section: Discussionmentioning

confidence: 99%

Identifying Robust Biomarkers for the Diagnosis and Subtype Distinction of Inflammatory Bowel Disease through Comprehensive Serum Metabolomic Profiling

Kim,

Suh,

Park

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Inflammatory Bowel Disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), presents diagnostic challenges owing to overlapping clinical presentations. This study aimed to delineate specific serum metabolomic biomarkers that differentiate IBD patients from healthy controls and further discriminate between CD and UC. Methods We enrolled a total of 346 participants, including 134 with CD, 124 with UC, and 88 normal controls (NC). Serum samples and their clinical metadata were systematically collected. Untargeted profiling was performed with Gas Chromatography-Time-Of-Flight-Mass Spectrometry, and targeted profiling of bile acids and tryptophan used Liquid Chromatography-Triple Quadrupole-Mass Spectrometry. The identification of distinct metabolites and potential biomarkers of IBD patients from NC and that of CD patients from UC were achieved through extensive univariate and multivariate statistical analyses which supplemented by Receiver Operating Characteristic (ROC) curves, pathways, and network analyses. Results Distinct clustering separated IBD patients from the NC, although the CD and UC subgroups overlapped in the non-targeted profiling. Targeted metabolomics revealed elevated tryptophan and indole-3-acetic acid levels in CD and UC patients. Increased kynurenine and indole-3-propionic acid levels were unique to CD, whereas UC was characterized by decreased indole-3-acetic acid, serotonin, and acetylcholine levels. Both IBD subtypes exhibited reduced primary-to-secondary bile acid ratios compared with the NC. The ROC analysis underscored the discriminatory power of the biomarkers (AUC values: NC vs. CD = 0.9738; NC vs. UC = 0.9887; UC vs. CD = 0.7140). Pathway analysis revealed alterations in glycerolipid metabolism, markedly differentiating UC from CD. Beta-alanine, arginine, and proline metabolism were linked to IBD compared to NCs. Network analysis correlated metabolomic markers with the clinical phenotypes of IBD. Conclusion Serum metabolomic biomarkers offer promising avenues for the diagnosis and subtype differentiation of IBD. Targeted metabolomics analysis is critical for distinguishing CD from UC.

show abstract

Section: Discussionmentioning

confidence: 99%

Identifying Robust Biomarkers for the Diagnosis and Subtype Distinction of Inflammatory Bowel Disease through Comprehensive Serum Metabolomic Profiling

Kim,

Suh,

Park

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Metabolic alterations in Crohn’s disease: A Systematic Review

Dev,

Kahlon,

Ruiz

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Crohn's disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract with an elusive etiology. There are multiple studies which reported dysregulated metabolites in IBD patients. However, there lies a great variability in the patient population, disease location, disease state, biological samples, and metabolite detection techniques across the studies. All these variables add to the great heterogeneity in the detected metabolites, making it difficult to achieve a disease specific comprehensive signature of the metabolites. Objective: We aimed to analyze CD specific metabolomic studies and available datasets to provide a most accurate and comprehensive signature of dysregulated metabolites and metabolic pathways implicated in human CD. Design: A comprehensive, systematic review search was carried out using Medline and Embase databases to search the studies (inception to May 2024) which used analytical chemistry techniques to quantify the metabolites in different biological samples of Crohn's patients and non-IBD controls. Metabolites significantly altered in Crohn's patients and reported in at least 2 studies were included and considered for further analysis. Results: The systematic search yielded 3,632 studies, with 88 selected for data extraction. Across these studies, 79 metabolites were found to be significantly altered in CD patients in two or more studies. These metabolites differentiate between Crohn's patients and non-IBD controls, showing a distinct signature within the biological samples of CD patients and their importance in pathophysiology of CD. Conclusion: This systematic review provides a comprehensive and categorical signature of dysregulated metabolites across biological samples and provide detailed insight into the perturbed metabolic pathways involved in CD.

show abstract

Underneath the Gut–Brain Axis in IBD—Evidence of the Non-Obvious

Boldyreva,

Evtushenko,

Lvova

et al. 2024

IJMS

View full text Add to dashboard Cite

The gut–brain axis (GBA) plays a pivotal role in human health and wellness by orchestrating complex bidirectional regulation and influencing numerous critical processes within the body. Over the past decade, research has increasingly focused on the GBA in the context of inflammatory bowel disease (IBD). Beyond its well-documented effects on the GBA–enteric nervous system and vagus nerve dysregulation, and gut microbiota misbalance—IBD also leads to impairments in the metabolic and cellular functions: metabolic dysregulation, mitochondrial dysfunction, cationic transport, and cytoskeleton dysregulation. These systemic effects are currently underexplored in relation to the GBA; however, they are crucial for the nervous system cells’ functioning. This review summarizes the studies on the particular mechanisms of metabolic dysregulation, mitochondrial dysfunction, cationic transport, and cytoskeleton impairments in IBD. Understanding the involvement of these processes in the GBA may help find new therapeutic targets and develop systemic approaches to improve the quality of life in IBD patients.

show abstract

Alterations of Serum Bile Acid Profile in Patients with Crohn’s Disease

Cited by 3 publications

References 25 publications

Identifying Robust Biomarkers for the Diagnosis and Subtype Distinction of Inflammatory Bowel Disease through Comprehensive Serum Metabolomic Profiling

Identifying Robust Biomarkers for the Diagnosis and Subtype Distinction of Inflammatory Bowel Disease through Comprehensive Serum Metabolomic Profiling

Metabolic alterations in Crohn’s disease: A Systematic Review

Underneath the Gut–Brain Axis in IBD—Evidence of the Non-Obvious

Contact Info

Product

Resources

About